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Abstract
We evaluated neoadjuvant ipilimumab in patients with surgically operable regionally advanced melanoma in order to
define markers of activity in the blood and tumor as assessed at baseline (before ipilimumab) and early on-treatment.
Patients were treated with ipilimumab (10 mg/kg intravenously every 3 weeks62 doses) bracketing surgery. Tumor and
blood biospecimens were obtained at baseline and at surgery. Flow cytometry and immunohistochemistry for select
biomarkers were performed. Thirty five patients were enrolled; IIIB (3; N2b), IIIC (32; N2c, N3), IV (2). Worst toxicities included
Grade 3 diarrhea/colitis (5; 14%), hepatitis (2; 6%), rash (1; 3%), elevated lipase (3; 9%). Median follow up was 18 months:
among 33 evaluable patients, median progression free survival (PFS) was 11 months, 95% CI (6.2–19.2). There was a
significant decrease in circulating myeloid derived suppressor cells (MDSC). Greater decrease in circulating monocyte gate
MDSC Lin12/HLA-DR2/CD33+/CD11b+ was associated with improved PFS (p = 0.03). There was a significant increase in
circulating regulatory T cells (Treg; CD4+CD25hi+Foxp3+) that, unexpectedly, was associated with improved PFS (HR= 0.57;
p = 0.034). Baseline evidence of fully activated type I CD4+ and CD8+ antigen-specific T cell immunity against cancer-testis
(NY-ESO-1) and melanocytic lineage (MART-1, gp100) antigens was detected and was significantly potentiated after
ipilimumab. In tumor, there was a significant increase in CD8+ T cells after ipilimumab (p = 0.02). Ipilimumab induced
increased tumor infiltration by fully activated (CD69+) CD3+/CD4+ and CD3+/CD8+ T cells with evidence of induction/
potentiation of memory T cells (CD45RO+). The change in Treg observed within the tumor showed an inverse relationship
with clinical benefit and greater decrease in tumor MDSC subset Lin12/HLA-DR2/CD33+/CD11b+ was associated with
improved PFS at one year. Neoadjuvant evaluation revealed a significant immunomodulating role for ipilimumab on Treg,
MDSC and effector T cells in the circulation and tumor microenvironment that warrants further pursuit in the quest for
optimizing melanoma immunotherapy.
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Introduction
Patients with palpable regional lymphatic involvement with
melanoma (AJCC stage IIIB-C) carry a risk of relapse and death
that approaches 70% at 5 years [1]. The development of local or
regional recurrence after initial surgical management portends an
even poorer prognosis [2–4]. In the Melanoma Surgical Trial, a
local recurrence was associated with 5 and 10 year survival rates of
9–11% and 5%, respectively [3].
Neoadjuvant therapy has been demonstrated to improve
outcome in the management of patients with multiple different
solid tumors [5–8]. A further significant advantage of the
neoadjuvant approach in relation to translational investigations
of new agents is the ability to evaluate the clinical and pathologic
responses, and the access to tumor tissue before and after
neoadjuvant therapy. This allows a direct assessment of the
antitumor mechanisms that may enable selective application of
therapeutic agents to those patients most likely to benefit.
Ipilimumab is a human immunoglobulin-G (IgG1)k anti-
CTLA-4 monoclonal antibody. It was approved by the U.S.
FDA for the treatment of advanced inoperable melanoma in
March 2011 at a dose of 3 mg/kg given every 3 weeks for 4 doses,
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based on the results of a phase III trial [9]. Prior data suggested a
dose dependent effect of ipilimumab from 0.3 mg/kg to 10 mg/
kg, where 10 mg/kg appeared to have the greatest efficacy, but the
rate of high-grade immune related adverse events (irAEs) was also
dose dependent [10]. Based on these and other data, ipilimumab
at 10 mg/kg was taken forward for phase II and phase III studies
including the CA184024 trial in metastatic disease combined with
dacarbazine [11] and the adjuvant trials EORTC18071 and
E1609 [12,13].
We had previously reported a significant immunomodulatory
impact of a CTLA4 blockade-based regimen on circulating
myeloid-derived suppressor cells (MDSC) and regulatory T cells
(Treg) in metastatic melanoma patients treated with that regimen
unlike patients treated with a peptide vaccination-based regimen
[14]. We hypothesized that similar changes in MDSC and Treg
may be observed with ipilimumab in the neoadjuvant/adjuvant
setting that may be best evaluated in a neoadjuvant study that
provides parallel evaluation in the circulation and the tumor
microenvironment (TME) of suppressor and effector immune cells.
We have therefore conducted a neoadjuvant translational
evaluation of ipilimumab at 10 mg/kg in patients with locally
and/or regionally advanced melanoma, with the primary goal of
generating biomarker data and providing a preliminary assessment
of efficacy and safety of neoadjuvant ipilimumab as secondary
endpoints. Primarily, we pursued the monitoring of cellular
markers of immunosuppression and of effector T cells before
and after ipilimumab as assessed in the TME and in the
circulation, testing the hypothesis that these biomarkers will be
significantly modulated and may have therapeutic predictive roles.
Such findings may be further tested in larger adjuvant trials
involving ipilimumab.
Patients and Methods
Patients
Ethics statement. The study was approved by the University
of Pittsburgh Institutional Review Board (IRB; IRB#
PRO09010033). All patients had a University of Pittsburgh IRB
approved written informed consent obtained. The study was
conducted in accordance with the principles expressed in the
Declaration of Helsinki. Eligible patients were 18 years or older
and had clinically detectable locally and/or regionally advanced
melanoma (cutaneous, mucosal or unknown primary).
Study Design and Treatment
A pre-treatment biopsy was required followed by 2 doses of
induction therapy with ipilimumab at 10 mg/kg intravenously
administered 3 weeks apart. Surgery was planned between weeks
6–8 following initiation of ipilimumab. Two doses of maintenance
ipilimumab were planned to be given 3 weeks apart following
recovery from surgery. Adjuvant high dose interferon-a (HDI) was
allowed in interferon-a naı¨ve patients. Blood specimens for this
project were collected at baseline and 6 weeks. Blood was drawn
into heparin (for peripheral blood mononuclear cells; PBMC)
tubes or tubes without anticoagulant (serum) and processed by the
Immunologic Monitoring Lab upon receipt. Tumors were
transported to the Tissue Procurement Facility after surgery in
sterile medium. Part of the tumor was formalin-fixed and paraffin-
embedded for immunohistochemistry, and part was enzymatically
digested to single cells and cryopreserved for Treg, MDSC and T
cell analysis.
Toxicity and Response Assessments
The descriptions and grading scales found in the NCI Common
Terminology Criteria for Adverse Events version 3.0 were utilized
for AE grading and reporting. For the purpose of response
assessment (modified WHO criteria), imaging studies were carried
out at baseline (before ipilimumab), 6–8 weeks after starting
ipilimumab (before surgery) then at 3 month intervals. Responses
were not confirmed radiologically due to the planned surgery.
Responses were classified as complete response (CR), partial
response (PR), stable disease (SD) or disease progression (PD).
Clinical benefit was defined as CR, PR or SD.
Statistical Methods
The study aimed to assess the effects of ipilimumab on the host
immune response, comparing assessments in the patients’ periph-
eral blood and tumor at baseline with corresponding follow up
evaluations made after 6 weeks of starting ipilimumab. The study
was planned for at least 28 patients with the ability to replace some
patients without adequate baseline tumor biopsy. A study of 28
patients was estimated to provide a 90% power to detect (at
significance level 0.05) a 1.63 fold to 1.78 fold increase in average
cell counts after 6 weeks of starting ipilimumab. The correspond-
ing detectable reductions in cell counts would range from 0.56 to
0.61.
Baseline descriptive statistics on all evaluable patients were
provided on demographic variables, laboratory parameters,
toxicity and efficacy. Survival and recurrence-free survival were
estimated by the Kaplan-Meier method.
Laboratory Methods and Corresponding Statistical
Analyses
Multicolor flow cytometry was used to compare cellular marker
expression on thawed PBMC and infiltrated tumor, before and
after treatment, focusing on circulating and intra-tumor regulatory
T cells (Treg) and myeloid derived suppressor cells (MDSC).
Healthy donor controls were run with the patient assays,
according to laboratory SOPs. Treg were defined as lymphocytes
expressing (1) CD4+/CD25hi+/intracellular FOXP3+ or (2)
CD4+/CD25hi+/CD39+ [15] compared to activated T cells which
expressed (CD3+CD4+CD25+). For the purposes of this study,
MDSC were defined as cells expressing (1) Lin12/HLA-DR2/
CD33+/CD11b+ lymphoid (small FSCxSSC) gate [16], (2) Lin12/
HLA-DR2/CD33+/CD11b+ monocyte (larger FSCxSSC) gate
[17–19] or (3) HLA-DR+ lo/CD14+ monocyte gate [20–24]. In a
subset of patients with sufficient cells, TIL were tested for
activation, memory, cytokine or effector molecule expression
(CD3, CD4, CD8, CD69, CD45RO, IFNc, TNFa, CD107a,
granzyme-B, perforin). Daily FC500-flow cytometer QC was run
using Beckman-Coulter Flow-Check, Flow-Check675 and Flow-
Check770 for laser alignment verification. Beckman-Coulter Flow-
Set fluorospheres were used to standardize voltages to ensure
consistency from day-to-day. Single-stained Beckman-Coulter
Immuno-Trol control cells were used to establish compensation
settings. For Treg analysis from thawed PBMC, cells were surface
stained for CD4 and CD25 with or without CD39 (Beckman-
Coulter), then permeabilized and stained for intracellular FOXP3
according to manufacturer’s instructions (eBioscience Foxp3
Staining Buffer-Set). The lymphocytes were gated by FSCxSSC,
then CD4+ cells were gated, then assessed for CD25-high and
FOXP3 positivity (with dot-plot and histogram gates set using
isotype control antibody stains). In addition, surface CD39 was
also tested. The ‘‘% circulating Treg’’ defined here was the % of
total CD4+ lymphocytes which were also CD25-high and FOXP3
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positive. For MDSC analysis from thawed PBMC, cells were
surface-stained for A) lineage cocktail (Becton-Dickinson, CD3/
CD14/CD16/CD19/CD20/CD56), CD11b, HLA-DR (both
Beckman-Coulter) and CD33 (Becton-Dickinson); or B) CD14
(Beckman-Coulter) and HLA-DR. Cells from tube-‘‘A’’ were then
gated by FSCxSSC for either lymphocytes (‘‘lymphoid gate
MDSC’’) or myeloid cells (‘‘monocyte gate MDSC’’), then for
lineage-negative+HLA-DR-negative, and then the myeloid subset
assessed for CD11b+/CD33+ cells (with dot-plot and histogram
gates set by isotype control antibody stains). Cells from ‘‘B’’ were
then gated on by FSCxSSC for myeloid cells, then for CD14+/
HLA-DRlo cells (with dot-plot and histogram gates set by isotype
control antibody stains). We used Beckman- Coulter CXP
Software version 2.1 and Beckman-Coulter Kaluza Software
version 1.2. Our goal for the cells of interest was 20,000 gated
events with a minimum of 10,000 gated events. Examples of raw
data are provided in Figure S3 (T-reg gating), Figure S4 (MDSC
gating) and Figure S5 (Antigen-specific CD4+ and CD8+ T cell
gating) (online only). Within-patient changes in Treg and MDSC
from baseline to week-6 were tested by Wilcoxon signed-rank test.
Within-patient changes in Treg and MDSC were also compared
between the patients with clinical benefit (CR/PR/SD) and those
with progression using the two-sample Wilcoxon rank-sum test.
Statistical analyses were performed using SAS (SAS Institute Inc.,
Cary, NC). A significance level was set at 0.05 and all P-values
reported were 2-sided and unadjusted.
To measure CD4+ and CD8+ T cells specific to tumor antigens
(Gp-100, MART-1, NY-ESO-1) in an HLA-unrestricted fashion,
libraries of 15-mer peptides overlapping by 4 amino acids were
constructed (Mimetopes, Minneapolis, MN), after Palucka et al
[25,26]. PBMC from baseline and 6 weeks, or infiltrated tumor
cells were co-cultured with peptide pools for 4 hours with
monensin, and then stained for surface CD3, CD4, CD8
(Beckman Coulter), CD69 (BD) and intracellular IFNc (eBios-
ciences). Controls included unstimulated cells and PMA/ionomy-
cin-stimulated PBMC. Within-patient changes were tested by
Wilcoxon signed-rank tests.
Immunohistochemistry. Paraffin-embedded tissue sections
(5 mm thick) were scored at 206 magnification by a surgical
pathologist (U.R.) who was blinded to patient and treatment
status. Immunohistochemical stains were performed with mouse
(FOXP3, Abcam Cat#ab22510; CD4, Dako Cat#M7310; CD8,
Dako Cat#M7103; CD11c, Leica Cat#NCL-L-CD11C-563;
CD45RO, Abcam Cat#ab23; CD20, Dako Cat#M075529-2)
and rabbit (CD86, Epitomics Cat#1858-1) monoclonal antibodies
as previously published [27]. The total numbers of intratumoral,
peritumoral, and perivascular mononuclear cell infiltrates were
enumerated at 206magnification and actual numbers determined
in four quadrants of the tissue, which often encompassed the entire
tissue section. All internal and external controls were appropriate.
Intensity of stains was optimal. The Wilcoxon singed-rank test was
used to compare the level of each marker between week 6 and
baseline. The Wilcoxon rank-sum test was used to compare the
marker level between patients with clinical benefit and those with
progression.
Results
Patient Characteristics
Thirty-five patients were enrolled between 2/2010 and 10/
2012. Eight patients were newly diagnosed and 27 had recurred
after prior treatment for melanoma that included surgery. One
patient had unknown primary melanoma, 5 mucosal and 29 had
cutaneous primaries including 3 with acral lentiginous melanoma.
Eighteen patients had a component of in-transit metastatic
melanoma. Overall staging/classification at study entry for those
newly diagnosed or as an estimated risk classification for those with
recurrent disease was IIIB (3; N2b) or IIIC (32; N2c, N3). For two
patients, retrospective review demonstrated stage IV disease
(Table 1).
Treatment Details
A total of 106 cycles of ipilimumab were administered (median
4/patient) (Table S1).
Efficacy
Two patients with stage IV disease were considered non-
evaluable for efficacy according to study protocol criteria,
including one cutaneous melanoma patient with bone marrow
metastatic involvement and one patient with uterine cervical
mucosal melanoma with pulmonary metastases. For the remaining
33 patients, the preoperative radiologic assessment (mWHO;
unconfirmed) by PET-CT scans 6–8 weeks after the initiation of
ipilimumab revealed 3 patients (9%) with an objective response (2
CR and 1 PR). Twenty-one patients (64%) had stable disease and
eight patients (24%) had disease progression. All patients had
histologically documented residual melanoma at definitive surgery
following 2 doses of ipilimumab, although 5 patients had only
microscopic disease detected. The median follow-up for patients at
risk of progression was 17.6 months and for patients who were still
alive was 16.1 months. The median progression-free survival (PFS)
was 10.8 months, 95% CI (6.2, 19.2). The probability of 6 and 12
months PFS was 0.72, 95% CI (0.53, 0.84) and 0.47, 95% CI
(0.29, 0.63). The probability of overall survival (OS) at 6 and 12
months was 0.97, 95% CI (0.78, 0.99). Figure S1 shows the
Kaplan–Meier plot of the probability of PFS. Six patients who
developed disease progression during follow up on study achieved
Table 1. Patient Demographics and Baseline Disease
Characteristics (N = 35 patients).
Variable No. of Patients (%)
Age, years; Median (range) 52 (30–87)
Cutaneous primary 29 (83)
Mucosal primary 5 (14)
Unknown primary 1 (3)
Gender: Female 13 (37)
Gender: Male 22 (63)
Performance status (ECOG): 0 22 (63)
Performance status (ECOG): 1 13 (37)
Recurrent disease after prior surgery 27 (77)
Prior adjuvant HDI* 12 (34)
Presence of in-transit metastases 18 (51)
Estimated risk stage: IIIB 3 (9)
Estimated risk stage: IIIC 30 (86)
Estimated risk stage: IV (non-evaluable for efficacy) 2 (5)
Tumor Mutational Status: BRAFV600 15 (43)
Tumor Mutational Status: NRASQ61 9 (26)
Tumor Mutational Status: NRAS R73 1 (3)
Tumor Mutational Status: Unknown 3 (9)
*HDI: high dose interferon-a; ECOG: Eastern Cooperative Oncology Group;
doi:10.1371/journal.pone.0087705.t001
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objective response or NED status with subsequent therapy (Table
S2).
Safety
Table 2 summarizes by severity the adverse events (AEs) that
were considered related to ipilimumab. No grade 4 or 5 immune
related AEs were observed. Autoimmune toxicities were success-
fully managed with corticosteroids.
Biomarkers
Peripheral cellular immune monitoring by multicolor flow cytometry
(N = 27 patients with available samples tested). Changes in
circulating Treg and MDSC were compared between baseline
and 6 weeks after ipilimumab. There was a significant increase in
the percentage of circulating Treg (CD4+CD25hi+Foxp3+ and
CD4+/CD25hi+/CD39+) as shown in Figure 1. Greater increase
in circulating Treg (CD4+CD25hi+Foxp3+) was found to be
associated with improved PFS (p = 0.034; HR = 0.57); Figure 2.
Greater increase in CD4+/CD25hi+ T cells was also associated
with improved PFS (p = 0.043; HR = 0.62).
In terms of MDSC, there was a decrease in the percentage of all
MDSC populations tested at 6 weeks as compared to baseline,
most significantly for the monocyte gate MDSC HLA-DR+lo/
CD14+ (p,0.0001); Figure 1. Greater decrease in circulating
monocyte gate MDSC Lin12/HLA-DR2/CD33+/CD11b+ was
associated with improved PFS (p = 0.03) as illustrated in Figure 3.
We detected evidence of spontaneous in vivo cross presentation
resulting in type I (interferon-c producing), fully activated (CD69+)
CD4+ and CD8+ antigen-specific T-cell immunity against cancer-
testis (NY-ESO-1) as well as melanocytic lineage (MART-1,
gp100) antigens in the absence of therapeutic vaccination. These
responses were significantly potentiated after ipilimumab as
assessed at 6 weeks (Figure S2). We classified the changes of T
cell response after ipilimumab as follows into (A) ,1.5 fold over
baseline, (B) 1.5–3 and (C) $3. Significant increases ($3fold) in
CD3+/CD4+/INF-c+ T-cells were seen only in patients who were
progression free at 6-months.
Immunohistochemistry (N = 24 patients with available samples
tested). In tumor, there was significant increase in CD8+ tumor
infiltrating lymphocytes observed after ipilimumab (p = 0.02) as
illustrated in Figure 4. No significant change in CD20+ B cells was
seen between baseline and 6 weeks. However, low levels of
baseline and post-treatment tumor CD20+ B cells tended to be
associated with worse clinical response (p = 0.07) and with worse
PFS (p = 0.06), respectively. Among the remaining antibodies
tested, no other significant findings by IHC were found.
Tumor immune monitoring by flow cytometry (N = 10 patients with
available samples tested). Compared to baseline, there was
increased tumor infiltration following ipilimumab by fully activat-
ed (CD69+) CD3+/CD4+ T cells (mean change = 19; SD = 14,
p = 0.06) and CD3+/CD8+ T cells (mean change = 11; SD = 19;
p = 0.2). There was evidence of induction/potentiation of memory
T cells expressing cytokine (CD3+/CD8+/CD45RO+/TNF-a+;
mean change = 1.38; SD = 1.46; p = 0.03) but not naı¨ve (CD3+/
CD8+/CD45RO2/TNF-a+; p = 0.44) T cells at 6 weeks.
There was a trend towards an inverse association between the
change in Treg in tumor and clinical-benefit (CR/PR/SD versus
PD; p = 0.09). CD4+CD25hi+FOXP3+ Tcells tended to be higher
at week 6 (mean change = 1.5; SD = 1.46) in the PD group while
the opposite was observed in the clinical-benefit group (mean
change =20.64, SD = 1.83). Greater decrease in tumor MDSC
Lin12/HLA-DR2/CD33+/CD11b+ was associated with im-
proved PFS at one year (p = 0.04).
Discussion
The neoadjuvant application of ipilimumab in this trial has
allowed the monitoring of the immunomodulatory effects of
ipilimumab in the circulation and the tumor microenvironment of
patients treated and the testing of mechanistic hypotheses.
Clinically, the evaluation of efficacy was meant to be descriptive
given the small sample size and the lack of a control group. The
study enrolled patients with melanoma recurrence and mortality
risk that is the highest among those considered potentially
Table 2. Adverse events (worst grade) that were possibly, probably or definitely related to ipilimumab (N= 35; incidence $2)*.
Type Sub-type All Grades Grade 1 Grade 2 Grade 3
No. Pts. % No. Pts. % No. Pts. % No. Pts. %
Immune mediated Adrenal Insufficiency 2 6 0 0 2 6 0 0
Amylase/Lipase 5 14 1 3 1 3 3 9
Diarrhea/Colitis 20 57 9 26 6 17 5 14
Hepatitis AST/ALT/AP/GGT 3 10 0 0 1 3 2 6
Hyper/pothyroidism 2 6 1 3 1 3 0 0
Hypopituitarism (low ACTH), Hypophysitis 2 6 0 0 2 6 0 0
Skin rash 20 57 11 31 8 23 1 3
Constitutional Fatigue 12 34 5 14 6 17 1 3
Fever 6 17 4 11 2 6 0 0
Pruritus 18 51 13 37 5 14 0 0
Other Gastrointestinal Nausea 8 23 7 20 0 0 1 3
Vomiting 4 11 2 6 1 3 1 3
Neuro-Psychiatric Depression/Anxiety 2 6 1 3 1 3 0 0
Other Infusion reaction 2 6 0 0 2 6 0 0
*One patient with a history of gastroesophageal reflux disease and irritable bowel syndrome developed grade 3 nausea, vomiting, gastroparesis and achalasia after one
dose of ipilimumab. One case of grade 4 uric acid elevation was considered possibly related to ipilimumab.
doi:10.1371/journal.pone.0087705.t002
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operable, including 27 patients with recurrent disease. In addition,
18 patients had a component of in-transit metastatic disease. The
PFS and OS rates observed may therefore be considered
favorable, with the noted caveats of the statistical limitations of
small single arm studies. The most common adverse events related
to ipilimumab were immune mediated, were consistent with the
known toxicity profile of this agent at 10 mg/kg and were
manageable utilizing established toxicity management guidelines
[9,11,28].
The outcomes of the peripheral monitoring of Treg and MDSC
as mediators of immune suppression were consistent with our prior
observations in patients with metastatic melanoma treated with the
combination of tremelimumab and HDI [14,29]. The significant
increase in circulating Treg paralleled an increase in the overall
CD4+ T cell population. This was expected with CTLA-4
blockade since Treg express CTLA-4 in basal conditions. More
interesting was the observation that a greater increase in
circulating Treg was associated with improved PFS. This raises
questions about the functional status of these Treg that should be
further pursued, although the opposite change in Treg was
observed in the TME and the clinical activity does not appear to
have been negatively affected by the circulating Treg increase.
These findings are consistent with our report of a similar impact of
tremelimumab/HDI on circulating Treg in metastatic melanoma
in the presence of significant clinical activity, but no post treatment
tumor samples were available to assess Treg in the TME in that
study [29]. Moreover, it is interesting to note that Me´nard et al.
had demonstrated that CTLA-4 blockade with tremelimumab in
advanced melanoma patients restored the circulating effector and
memory CD4+ and CD8+ T cell pool and TCR-dependent T-cell
proliferation that became resistant to Treg-mediated suppression
[30]. In tumor, in this study, there was a trend towards an inverse
association between the change in Treg after ipilimumab and
clinical outcome. Hamid, et al reported a significant association
between high baseline tumor FOXP3 expression by IHC and
improved clinical outcome after ipilimumab treatment for
metastatic melanoma supporting a role for ipilimumab in
modulating intra-tumoral Treg [31]. We examined CD4+CD25hi-
FOXP3hi Treg, the most frequently examined ‘‘nTreg’’ subset. In
an exploratory analysis, we examined the Treg for the suppressive
ectonucleotidase CD39 and on average, they were 55% positive
(range 15–93% positive), further indicating suppressive nTreg
[32].
In monitoring MDSC in metastatic melanoma patients treated
with the combination of tremelimumab/HDI, we first reported a
significant regulatory impact on these cellular mediators of
immunosuppression in a trial involving CTLA-4 blockade [29].
We have now documented a similar regulatory impact of
ipilimumab alone upon MDSC in the neoadjuvant setting. This
effect of ipilimumab was also seen in tumor where a greater
Figure 1. Forest plot of the multicolor flow cytometry data comparing the cell surface marker expression of regulatory T cells (Treg)
and myeloid-derived suppressor cells (MDSC) on peripheral blood mononuclear cells (PBMC) at baseline and following treatment
with ipilimumab (6 weeks). The plot represents average within-patient changes from baseline to 6 weeks (with corresponding 95% confidence
intervals). Treg were defined as cells expressing (1) CD4+CD25hi+FOXP3+ or (2) CD4+CD25hi+CD39+ activated T cells (CD3+CD4+CD25+). MDSC were
defined as cells expressing (1) Lin12/HLA-DR2/CD33+/CD11b+ lymphoid gate, (2) Lin12/HLA-DR2/CD33+/CD11b+ monocyte gate or (3) HLA-DR+lo/
CD14+ monocyte gate (N= 27 patients). Examples of raw data are provided in Figures S3 (T-reg gating) and S4 (MDSC gating).
doi:10.1371/journal.pone.0087705.g001
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decrease in tumor MDSC was associated with improved PFS at
one year. While there is substantial variation in identification of
human MDSC, we examined three different subsets which have
been supported by previous studies, and found that the CD14+/
HLA-DRlo subset was highly significantly changed, which is a key
MDSC subset in the recent study of Walter et al [33]. Decrease in
Figure 2. Kaplan-Meier plot of progression free survival (PFS) by the dichotomized (at median) change in the percentage of
circulating regulatory T cells (Treg) between baseline and week 6. Greater increase in circulating Treg (CD4+CD25hi+Foxp3+%) was
associated with improved PFS (HR= 0.57, p = 0.034; N= 27 patients). Example of raw data is provided in Figure S3 where the gating strategy used for
Treg is shown.
doi:10.1371/journal.pone.0087705.g002
Figure 3. Kaplan-Meier plot of progression free survival (PFS) by the dichotomized change in the percentage of circulating MDSC
between baseline and week 6. Greater decrease in circulating monocyte gate MDSC (Lin12/HLA-DR2/CD33+/CD11b+%) was associated with
improved progression free survival (PFS; p = 0.03; N= 27 patients). Example of raw data is provided in Figure S4 where the gating strategies used for
MDSC subsets are shown.
doi:10.1371/journal.pone.0087705.g003
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the Lin2/CD11b+/CD33+ monocyte subset was significantly
correlated with improved PFS, which was also seen in other
cancer settings [17,19], and was a particularly suppressive subset
examined in renal cell carcinoma and sarcoma patients [34].
These observations with Treg and MDSC at baseline as well as
early on-treatment support a significant immunomodulatory role
of anti-CTLA-4 therapy in relation to the Treg and MDSC host
responses. They support further testing of these mediators of
immune suppression as predictors of clinical benefit as baseline or
early-on-treatment markers.
Patients were not immunized with defined tumor antigens,
however we hypothesized that ipilimumab might allow the
development of T cell responses to antigens expressed by
melanoma or allow the expansion of spontaneous immunity. We
detected evidence of in-vivo cross presentation of immunogenic
shared melanoma tumor antigens, and stimulation of tumor
antigen-specific type I, activated, CD4+ and CD8+ T cell responses
at baseline that were augmented with ipilimumab therapy in the
blood. Cellular responses were detected against cancer-testis (NY-
ESO-1) as well as melanocytic lineage (MART-1, gp100) antigens
in the absence of vaccination. This observation, at the least, does
not support a therapeutic utility for exogenous tumor immuniza-
tion in combination with ipilimumab in the absence of evidence of
benefit to date. It is noteworthy that the pivotal phase III study of
ipilimumab at 3 mg/kg with or without gp100 peptide vaccine in
metastatic melanoma showed no added therapeutic impact of the
peptide vaccine compared to ipilimumab monotherapy [9]. Our
observation that the most significant increases ($3 fold) in CD3+/
CD4+/IFN-c+ T cells was seen only in patients who remained
progression-free at 6-months supports further exploring this
cellular subpopulation as a potential tool for early assessment of
treatment outcome. This potential therapeutic predictive tool is
similar to the observation by Carthon, et al in relation to
CD4+ICOShi T cells [35]. In bladder cancer patients treated
preoperatively with ipilimumab, CD4+ and CD8+ ICOShi T cells
were increased compared with baseline, and patients with clinical
benefit at week 24 had persistent elevation in the percentage of
CD4+ICOShi T cells; only 1/7patients with progressive disease or
death at week 24 had persistent elevation in the percentage of
CD4+ICOShi T cells [35].
By IHC, we observed a significant influx of CD8+ T cells into
tumor following ipilimumab. It was interesting to note evidence of
induction/potentiation of T cell memory (CD45RO+) but not
naı¨ve (CD45RO2) T cells in the tumor biopsies examined by flow
cytometry. Taken together with the data of Galon, et al [36,37]
regarding the prognostic value of CD3+, CD8+ and CD45RO+
cells in relation to survival in colorectal cancer, our data suggest a
role for ipilimumab in inducing and/or potentiating such effector
elements in tumor, eventually translating into the clinical benefits
seen with this agent. This is in addition to a potential therapeutic
predictive role for these biomarkers that can be assessed in tumor
biopsies obtained at baseline or early on-treatment.
Low baseline tumor infiltrating CD20+ B cells showed a trend
towards association with worse clinical response (p = 0.07; N = 24).
While not statistically significant, this trend is interesting in view of
the report by DiLillo, et al that B cell depletion in mice enhanced
Figure 4. Immunohistochemistry (IHC) of CD8+ tumor infiltrating lymphocytes (TIL). There was a significant increase in CD8+ T cells from
baseline to week 6 (Wilcoxon signed-rank test p = 0.02; N= 24 patients). (A) Boxplots of IHC scores of CD8+ TIL at baseline and week 6. Total counts
from the same patient at the two time points are connected by light gray lines. (B) Plot of the median change in CD8+ TIL at week 6 (compared to
baseline) with corresponding 95% confidence intervals. (C–D) Example of baseline and week 6 tumor CD8+ TIL (stained brown) by IHC. Magnification:
206.
doi:10.1371/journal.pone.0087705.g004
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B16 melanoma outgrowth [38]. These authors suggested that B
cells are required for optimal CD4+ and CD8+ T cell tumor
immunity, noting that effector-memory and IFNc– or TNFa–
secreting CD4+ and CD8+ T cell induction was significantly
impaired in B cell-depleted mice with tumors. In addition, tumor
Ag-specific CD8+ T cell proliferation was impaired in tumor-
bearing mice lacking B cells. Slingluff et al, studying immune cells
infiltrating the microenvironment of melanoma metastases found
that B cells are correlated with increased survival [39]. These and
our observations argue for further research into the role of B cells
in the tumor microenvironment and the potential supportive role
of B cells for optimal CD4+ and CD8+ T cell tumor immunity.
They also support further investigations into the therapeutic
predictive value of in-tumor B cells, possibly as part of a predictive
immune signature.
Conclusions
This neoadjuvant approach to the evaluation of ipilimumab in
high-risk locally/regionally advanced melanoma has revealed
baseline and early on-treatment biomarkers of immunomodulation
that provide insight to the mechanism of ipilimumab, and warrant
further pursuit in future studies aiming to individualize and
optimize the immunotherapy of melanoma.
Supporting Information
Figure S1 Kaplan – Meier plot of the probability of
progression-free survival (N=33). The estimated medi-
an is 10.8 months (95% Confidence Interval = 6.2, 19.2).
(TIF)
Figure S2 Forest Plot of Type I CD4 and CD8 Antigen-
specific T Cell Immunity (N=27). T cell immunity to shared
melanoma antigens was measured with peptide pools, as described
in the methods. Activated (CD69+) and IFNc-producing T cells
were measured.
(TIF)
Figure S3 The gating strategy used for regulatory T
cells (Treg) is shown. Lymphocytes were gated on, and
the CD4+CD25hi+ were gated on, and then histograms
show the % intracellular FOXP3 and % surface CD39+
on those CD4+CD25hi+ lymphocytes. A representative
patient sample is shown.
(TIF)
Figure S4 The gating strategies used for MDSC subsets
are shown. The lymphocyte, monocyte and granulocyte
populations are shown by FSC and SSC. The lineage negative
(lin2) HLA-DRneg cells were then gated on, and the percent of
CD11b+/CD33+ cells were enumerated. Alternatively, the CD14+
monocytes were gated on and the HLA-DRlo+ cells were identified
by histogram (bottom left). A representative patient sample is
shown.
(TIF)
Figure S5 The gating strategy for identification of
melanoma tumor antigen-specific CD8+ and CD4+ T
cells is shown. Lymphocytes were gated on, and the CD3+/
CD8+ (top) or CD3+/CD4+ (bottom) were gated on. These cells
were then assayed for CD69 and intracellular IFNc. Shown are
negative controls, PMA/ionomycin-stimulated positive control
and responses NY-ESO-1 peptides. A representative patient
sample is shown.
(TIF)
Table S1 Summarizes ipilimumab administration pre-
sented by the cycle of ipilimumab and the corresponding
number of patients treated.
(DOC)
Table S2 Six patients who developed disease progres-
sion during follow up on study achieved objective
response or no evidence of disease (NED) status with
subsequent therapy.
(TIF)
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